Skip to main content
Erschienen in: BMC Pulmonary Medicine 1/2020

Open Access 01.12.2020 | Case report

Extensive eye-oral-bronchial mucosal nodules with eosinopgillia: a rare case report and literature review

verfasst von: Lujin Wu, Qianru Leng, Yan Wang, Daowen Wang, Danlei Yang

Erschienen in: BMC Pulmonary Medicine | Ausgabe 1/2020

Abstract

Background

Mucosal nodules can be caused by infection, inflammation and neoplastic disease. Many noninfectious diseases, such as eosinophilia, amyloidosis, sarcoidosis, Wegener’s granuloma, langerhans cell histiocytosis etc., are associated with the formation of multisytem mucosal nodules, especially significant bronchial lesions. Detailed medical history, comprehensive metabolic profile, biopsy specimen and imaging examinations are required for differentiating among these disorders. The process of diagnosis and treatment of our patient’s mucosal nodules was challenging, which could be helpful to similar cases.

Case presentation

We represent a case of a 29-year-old woman with plentiful nodules of unknown origin on extensive mucous membranes. Biopsy specimen reports inflammatory lesions with large numbers of neutrophils, lymphocytes, and varying degrees of eosinophils. Treatment of anti-infection, anti-tussive and anti-allergic was ineffective, but glucocorticoid showed great improvement to her symptoms.

Conclusion

We experienced a rare case with plentiful nodules of unknown origin on extensive mucous membranes. She may be a specific phenotype of eosinophilia or may be a novel multisystem disease with respiratory system as the primary symptom. The diagnosis of our patient remains unclear, but tentative glucocorticoid therapy was beneficial.
Hinweise
Lujin Wu and Qianru Leng contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
PAP
Pulmonary alveolar proteinosis
LAM
Lymphangioleyomiomatosis
ESR
Erythrocyte sedimentation rate
Hs-CRP
High sensitivity C-reactive protein
HIV
Human immunodeficiency virus
NGS
Next generation sequencing
HES
Hypereosinophilic syndrome
AEC
Absolute eosinophil count
CSS
Churg-strauss syndrome
EGPA
Eosinophilic granulomatous polyvasculitis
ANCA
Antineutrophil cytoplasmic antibody
TBA
Tracheobronchial amyloidosis
PLCH
Pulmonary Langerhans cell histiocytosis
LCH
Langerhans cell histiocytosis
WG
Wegener Granulomatosis

Background

Rare diseases are conditions that affect a small proportion of the population; the definition of rare disease varies from country to country due to the influence of region and population base. In the USA they are described as affecting fewer than 200,000 people (https://​rarediseases.​info.​nih.​gov), and in Europe as affecting fewer than one in 2000 (https://​www.​eurordis.​org/​about-rare-diseases). In China, the incidence rate is defined as less than one in 10,000 newborns and less than one in 500,000 people [1]. There are many kinds of rare diseases of respiratory system, which are easy to be missed and misdiagnosed in clinic. Current reports include: langerhans cell histiocytosis, eosinophilia, pulmonary alveolar proteinosis (PAP), lymphangioleyomiomatosis (LAM), bronchial amyloidosis, Wegener’s granuloma, Kartagener syndrome, bronchial mucosal tuberculosis, osteomalacia, etc. [24]. We treated a patient with recurrent cough and expectoration, accompanying with multiple nodules in the oral mucosa and ophthalmic conjunctiva. Bronchoscopy, laryngoscopy and gastroduodenoscopy confirmed that widespread and dense nodules were distributed in the trachea, left and right bronchus, posterior pharyngeal wall and esophagus. In addition, the patient had congenital cleft palate and dextroversion of heart. Pathological and etiological examination were mainly characterized by inflammatory lesions with large numbers of neutrophils, lymphocytes, and varying degrees of eosinophils. The examination results also excluded specific pathogen infection, granulomatous disease, amyloidosis, calculosis, and neoplastic diseases. Treatment with a variety of antibiotics was invalid but tentative glucocorticoid therapy was beneficial. This patient may be a specific phenotype of eosinophilia or may be a novel multisystem disease with respiratory system as the primary symptom.

Case presentation

A 29-year-old non-smoking woman was referred to our department for repeated coughing and expectoration for more than 4 months and gradual appearance of eye and mouth nodules. At start in May 2019, the patient felt pain in her eyes with pustules developing around them. Later the patient began to experience pharyngeal itching, cough, expectoration, fatigue and occasional chest distress. There was no history of fever, night sweats, loss of appetite or weight, joint pains, rash, hair fall, oral ulcer, photophobia and decreased vision. She received intravenous antibiotics at local community hospital for a week but the curative effect was poor. On July 22, 2019, she was firstly admitted to Wuhan Union Hospital on suspicion of bronchial asthma. Physical examination revealed that both lungs had sporadic wheezing. Her ESR was 103 mm/H (normal range 0–20 mm/H) and IgE was 159.30 IU/ml (normal range 0–100 IU/ml). Pulmonary function examination showed severe mixed pulmonary ventilation dysfunction and bronchial dilation test (negative). Chest CT showed that the right upper lobe had minute nodules; the right lower lobe had proximal segmental lung insufficiency; the right paraspinal pleura was slightly thickened; the mediastinal lymph nodes were increased; and the wall of the esophagus was limited and slightly thickened. The patient was treated with piperacillin sulbactam sodium, loratadine and montelukast sodium. After a few days of symptom remission, her cough and expectoration aggravated again. On presentation to our institution on September 12, 2019, she had plentiful nodules on her eyelids and oral mucosa with uranoschisis in the upper jaw (Fig. 1).
Past medical history: in 2012, she underwent reduction surgery in Hubei provincial people’s hospital due to congenital dextrocardia. She denied any medical histories about tuberculosis, hepatitis, hypertension, diabetes and rheumatic immune diseases. The patient also had no history of allergies or blood transfusions. The patient declared no family history of any relevant conditions.
On examination, cell counts of white blood (12.12×10^9/L, normal range 3.5–9.5×10^9/L), neutrophils (8.27×10^9/L, normal range 1.8–6.3×10^9/L) and eosinophil (1.27×10^9/L, normal range 0.02–0.52×10^9/L) increased. Additionally, the ESR (34 mm/H, normal range 0-20 mm/H), hs-CRP (8.1 mg/L, normal range 0-1 mg/L) and IgE (178.8 IU/ml, normal range 0–100 IU/ml) also increased. Other laboratory workup including liver and renal functions, anti-cardiolipid antibody, antinuclear antibody, antistreptococcal O titers, rheumatoid factors, thyroid function, HIV antibody quantification did not reveal any abnormalities. No obvious abnormality was found in abdominal viscera and vascular ultrasound, cardiac function and electrocardiogram. There was no significant change in chest CT compared with the last CT (Fig. 2). To explore the etiology, we performed bronchoscopy to collect alveolar lavage fluid and biopsy. Fiberbronchoscopy showed that a large number of small bulges were densely distributed in the whole trachea, carina and bronchi, covered with more white viscous secretions. The surface of these bulges was smooth. Blood vessels were abundant and easy to bleed. The openings of the right middle lobe, the right lower lobe and the left upper lobe bronchial were markedly narrowed (Fig. 3). The smear and culture of bronchial lavage fluid didn’t show any evidence of bacteria, fungi, or tuberculosis. Next generation sequencing (NGS) technology only found a low copy number of haemophilus parainfluenzae (191) and rothia aeria (163). Laryngoscopy and gastroduodenoscopy showed that abundant yellow-white tuberculous uplifts were widely distributed in the posterior pharynx wall and inferior segmental esophagus (Fig. 3).
Biopsy specimens of bronchial nodules showed that part of the respiratory epithelium was squamous metaplasia with granulation tissue proliferating below, with numerous neutrophils and eosinophils infiltrating. No caseous necrosis, granulomatous lesions and tumor were observed in the sections. Immunohistochemical hinted that acid fast staining (−), congo red staining (−), CD34 (+), S-100 (−), CD1a (−), Langerin (−) (Fig. 4). Biopsy specimens of oral nodules showed a large amount of histiocytosis (some were foam cells) and neutrophil infiltration (the formation of a small abscess), with a small amount of eosinophils and lymphocytes infiltration in the subepithelial and salivary gland tissues without any caseous necrosis, obvious granulomatous lesions and neoplastic lesions (Fig. 5). Immunohistochemical showed that CD163(+), CD68(+), CD45-LCA(+), S-100(+), CD35(+), SMA(−), desmin(−), HMB45(−), Melan-A(−), Cathepsin K(−), SOX10(−), CD21(−), CD23(−), Langerin(−), mutated Braf (V600E)(−), Eber(−), CyclinD1(+), Ki67(+) (Fig. 5). Similarly, biopsy specimens of esophageal nodules only found numerous neutrophils and eosinophilic granulocyte infiltration (Fig. 5). Bone marrow examination showed no abnormality and rearrangement of FlP1L1/PDGFR gene which was associated with the negative result of primary hypereosinophilic syndrome (HES). These findings did not point specifically to a particular disease but were very similar to eosinophilia. She may be a specific phenotype of eosinophilia or may be a novel multisystem disease with respiratory system as the primary symptom, so we tried several treatment plans.
At first, the patient was treated with anti-infection (cefoperazone), anti-allergy (montelukast), anti-tussive (methoxyphenamine) and expectorant (ambroxol). However, these treatments showed few benefit after a month. In consideration of the extensiveness of the lesions, surgical resection was unfeasible. Thus, we tentatively gave her glucocorticoid (dexamethasone) 20 mg q.d, somac (pantoprazole) 40 mg q.d, caltrate D 300 mg q.d and arranged close follow-up. A month later, the symptoms of cough, expectoration, oral and eye mucosa nodules disappeared. The number of nodules on tracheal and bronchial mucosa also significantly reduced (Fig. 6).
In general, we found a strange disease in which patients presented recurrent cough and sputum, chest tightness, accompanied with extensive nodules of eye-mouth-bronchial mucosa. The biopsy specimen mainly showed inflammatory lesions (concluding a large number of neutrophils, moderate eosinophils and a small number of lymphocytes) and some granulation tissue proliferating, without caseoid necrosis and granuloma. Additionally, glucocorticoid rather than antibiotics was effective. Although it is not known whether this is related to the patient’s multisystem mucosal lesions, the patient also had a congenital dextrocardia and palatoschisis.

Discussion and conclusions

Mucosal nodules are visible as rounded, elliptic, or irregular hyperplasia initiated by tumour, infection, autoimmunity, trauma or foreign matter [5]. Many noninfectious diseases, such as eosinophilia, amyloidosis, sarcoidosis, Wegener’s granuloma, langerhans cell histiocytosis, foreign bodies ect., are associated with the formation of mucosal nodules, especially significant bronchial lesions [4, 68]. Here we introduce the differential diagnoses and literature review of several rare bronchial diseases.

Eosinophilia

The definition of eosinophilia is the absolute eosinophil count (AEC) in the peripheral blood is more than 0.5 × 109/L with a percentage greater than 5% [9, 10]. The clinical features were varied, including weakness and fatigue, cough and fever, myalgias, dyspnea, and rash [11]. All organ systems are sensitive to sustained eosinophilia. Infiltrative dermopathy, pulmonary and gastrointestinal lesions accounted for the top three clinical manifestation in patients with hypereosinophilia [12]. Common causes of eosinophilia include helminthic parasite infections, varied types of adverse reactions to medications, and collagen vascular disease (Churg-Strauss syndrome, systemic lupus erythematosus), and primary myeloid tumor [13]. Additionally, we noticed a possible link between cleft lip/palate and eosinophilia. Several researches have indicated that eosinophilia was seen in 20–25% of cleft lip/palate cases [14, 15], but the evidences are not enough to verify their connection, so further studies are required to draw a clear conclusion. In the treatment of eosinophilia, the necessary therapy is removing causes. Systemic corticosteroids are the initial treatment at present when confronted with a patient with unexplained eosinophilia [16]. Although plasma eosinophilia and the presence of a large number of eosinophils in the lesion suggested that this case may be a secondary eosinophilia, extensive multisystem mucosal nodules in eosinophilia patients were not reported as prominent.

Churg-strauss syndrome

In 1951, Churg and Strauss firstly described Churg-strauss syndrome (CSS) as a systemic antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Hypereosinophilic disorder with lung involvement frequently occurs in people with asthma [17]. Based on the presence or absence of an ANCA, CSS were divided into two subtypes [18, 19]. Thus, ANCA positive is not requirement for CSS diagnosis. The pathological feature of CSS is a necrotizing vasculitis of medium to small sized blood vessels (veins and arteries) associated with eosinophilic infiltration around the vessels and adjacent tissues [17]. A combination of high-dose corticosteroids and cyclophosphamide is still the gold standard for the treatment of CSS [20]. Our patient had no history of asthma; the pathology reports of the patient didn’t suggest necrotizing small vasculitis; and ANCA test was negative, above which excluded the diagnosis of CSS.

Tracheobronchial amyloidosis (TBA)

Tracheobronchial amyloidosis (TBA) is a rare disorder induced by abnormal deposition of excessive insoluble amyloid fibrils in the submucosa of respiratory tract [21]. Amyloid deposits can be focal, diffuse, or form localized masses, leading to various morphology. Based on the sites and severity of lesions, the clinical symptoms of TBA patients may vary from mild to severe, usually including flu-like symptoms, progressive dyspnea, and even respiratory failure [22]. Trachea, main bronchus, lobar bronchi, and segmental bronchi are the main lesion sites in TBA patients, while it has little impact on small airways and alveoli [23]. Chest X-ray is generally normal, but CT shows thickening of the tracheal walls, with narrowing of the tracheal lumen [24]. Bronchoscopy has a more important value in TBA diagnosis and can detect specific morphological changes, usually manifesting as single or multiple nodules or masses in tracheal and bronchial lumens, resulting in tracheal stenosis or occlusion [25]. Histopathological biopsy under bronchoscopy is listed as the gold standard for diagnosis of TBA. The characteristic change is that amyloid under tracheobronchial mucosa shows brick-red under light microscope and yellow-green birefringence under polarizing microscope after stained by Congo red [26]. Although the morphological changes under bronchoscopy of this patient seem to be similar with TBA, the pathological changes, especially Congo red negative, are not consistent with this disease.

Pulmonary langerhans cell histiocytosis (PLCH)

Pulmonary langerhans cell histiocytosis (PLCH) is a rare granulomatous disorder characterized by the infiltration of dendritic cells sharing phenotypic similarities with langerhans cells in lesions [27]. Long-term smoking is an important driver. LCH may involve multiple organs at the same time, such as bones, skin, pituitary gland, lymph nodes, liver, spleen, etc. In the lungs, a nodular proliferation of langerhans cells often occurs in the bronchial mucosa and the alveolar septa, accompanied with the infiltration of eosinophilic granulocytes and destruction of the bronchial wall [28]. Langerhans cells can be selectively labeled by CD1a and langerin antibodies, which are the gold standard diagnostic modality [29, 30]. However, the immunohistochemistry of this patient revealed that both CD1a and langerin were negative which were not supported this disease.

Wegener Granulomatosis (WG)

Wegener Granulomatosis (WG) is a rare autoimmune disease and is most common between 40 and 50 years of age. It is a systemic disease characterized by respiratory necrotizing, granulomatous vasculitis, glomerulonephritis, and vasculitis of other organs [31]. When skin and mucous membrane are involved, purpura, erythema, papules, pustules, subcutaneous nodules and ulcers are susceptible in lower limbs, but you can also find them on the trunk, upper limbs and maxillofacial region. Fibrolaryngoscopy or direct laryngoscopy showed typical subglottic annular stenosis with a surface of red brittle mucosa or erosive granulation tissue. Strawberry - like gingival hyperplasia is characteristic of WG in oral cavity [32]. CT findings were subglottic stenosis and thickening of the surrounding mucosa, as well as irregular changes in the trachea and bronchial walls and ulcerations [33]. The pathological features were the infiltration of neutrophils and mononuclear cells on the walls of pulmonary small blood vessels, with granulation of giant cells and multinucleated giant cells. Serology character of WG is the presence of anti-neutrophil cytoplasmic antibody (ANCA) to protease 3 (PR3, [34]). The results of ANCA test, renal function, urinalysis, imaging tests, and bronchoscopy of our patient didn’t support the diagnosis of WG.

Sarcoidosis

Sarcoidosis is a multisystemic granulomatous disease of unknown etiology characterized by noncaseous necrotic granuloma. Between 30 and 60% of patients with sarcoidosis have no clinical symptoms and are diagnosed on X-ray during routine physical examination. Among those with symptoms, the most common ones are respiratory symptoms, rash, systemic symptoms, and musculoskeletal symptoms [35, 36]. The disease usually manifests as bilateral hilar lymph node enlargement, intrapulmonary infiltration, eye and skin infiltration, as well as liver, spleen and salivary glands [37]. Pulmonary imaging manifestations of sarcoidosis can be varied. Typical imaging features of chest involvement are mediastinal lymph node enlargement or bilateral hilar lymph node symmetry enlargement. Non-caseous necrotizing granuloma is the typical pathological feature of sarcoidosis [35], which was not consistent with our patient.
Treatments for respiratory system nodule diseases change over different diagnoses. For infectious nodules, adequate antibiotics, antifungal, or antiparasitics can help with recovery. Some inflammatory nodules could spontaneously alleviate without treatment [38, 39]. For eosinophilic angiocentric fibrosis and some fungal granulomas, surgical resection is a valid treatment. In the treatment of eosinophilia, sarcoidosis, Wegener’s granuloma, fungoid granuloma and other inflammatory nodule diseases, glucocorticoids are proved to be effective [38, 39].
In conclusion, we recognize the rarity of the disorder and lack of etiological diagnosis in our case. Generally, we can differentiate the type of nodule lesions on the basis of detailed medical history, comprehensive metabolic profile, imaging examination and biopsy specimen [39]. When the disorder type is difficult to determine, an attempt of glucocorticoid is worthy. In this rare case, the diagnosis of our patient remains unclear, she may be a specific phenotype of eosinophilia or may be a novel multisystem disease with respiratory system as the primary symptom. Clinical follow-up and gene detection are planned to provide accurate diagnosis and further treatments.

Acknowledgements

Not applicable.
This study was approved by Ethics Committee of Tongji Hospital affliated with Tongji Medical College, Huazhong University of Science and Technology and the patient signed an informed consent prior to enrolment.
Written informed consent was obtained from the patient for publication of this case report.

Competing interests

The authors have no competing interests to declare.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Ma D, Li DG, Zhang X, He L. The prevention and treatment on rare diseases in China: opportunities and challenges. Chinese J Evidence Based Pediatr. 2011;6:81–2 (in Chinese). Ma D, Li DG, Zhang X, He L. The prevention and treatment on rare diseases in China: opportunities and challenges. Chinese J Evidence Based Pediatr. 2011;6:81–2 (in Chinese).
2.
Zurück zum Zitat Harari S, Cottin V, Humbert M. Global effort against rare and orphan diseases. Eur Respir Rev. 2012;21(125):171–2.PubMedCrossRef Harari S, Cottin V, Humbert M. Global effort against rare and orphan diseases. Eur Respir Rev. 2012;21(125):171–2.PubMedCrossRef
3.
Zurück zum Zitat Pogue RE, et al. Rare genetic diseases: update on diagnosis, treatment and online resources. Drug Discov Today. 2018;23(1):187–95.PubMedCrossRef Pogue RE, et al. Rare genetic diseases: update on diagnosis, treatment and online resources. Drug Discov Today. 2018;23(1):187–95.PubMedCrossRef
4.
Zurück zum Zitat Harari S, Humbert M. Rare pulmonary diseases: a common fight. Eur Respir Rev. 2017;26(145):170059.PubMedCrossRef Harari S, Humbert M. Rare pulmonary diseases: a common fight. Eur Respir Rev. 2017;26(145):170059.PubMedCrossRef
5.
Zurück zum Zitat Kim H, et al. Outcome of incidentally detected airway nodules. Eur Respir J. 2016;47(5):1510–7.PubMedCrossRef Kim H, et al. Outcome of incidentally detected airway nodules. Eur Respir J. 2016;47(5):1510–7.PubMedCrossRef
6.
Zurück zum Zitat Spagnolo P, du Bois RM, Cottin V. Rare lung disease and orphan drug development. Lancet Respir Med. 2013;1(6):479–87.PubMedCrossRef Spagnolo P, du Bois RM, Cottin V. Rare lung disease and orphan drug development. Lancet Respir Med. 2013;1(6):479–87.PubMedCrossRef
7.
Zurück zum Zitat Harari S, et al. Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to? Eur Respir Rev. 2015;24(137):375–7.PubMedCrossRef Harari S, et al. Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to? Eur Respir Rev. 2015;24(137):375–7.PubMedCrossRef
9.
Zurück zum Zitat Butt NM, et al. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017;176(4):553–72.PubMedCrossRef Butt NM, et al. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017;176(4):553–72.PubMedCrossRef
10.
Zurück zum Zitat Tefferi A. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc. 2005;80(1):75–83.PubMedCrossRef Tefferi A. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc. 2005;80(1):75–83.PubMedCrossRef
11.
Zurück zum Zitat Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92(11):1243–59.PubMedCrossRef Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92(11):1243–59.PubMedCrossRef
12.
Zurück zum Zitat Montgomery ND, et al. Diagnostic complexities of eosinophilia. Arch Pathol Laboratory Med (1976). 2013;137(2):259–69.CrossRef Montgomery ND, et al. Diagnostic complexities of eosinophilia. Arch Pathol Laboratory Med (1976). 2013;137(2):259–69.CrossRef
13.
Zurück zum Zitat Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006;133(5):468–92.PubMedCrossRef Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006;133(5):468–92.PubMedCrossRef
14.
Zurück zum Zitat Singhal S, et al. Hematological parameters in patients of cleft lip and cleft palate with special reference to eosinophil counts. J Craniofac Surg. 2014;25(1):103–5.PubMedCrossRef Singhal S, et al. Hematological parameters in patients of cleft lip and cleft palate with special reference to eosinophil counts. J Craniofac Surg. 2014;25(1):103–5.PubMedCrossRef
15.
Zurück zum Zitat Dvivedi J, Dvivedi S. A clinical and demographic profile of the cleft lip and palate in sub-Himalayan India: a hospital-based study. Indian J Plast Surg. 2012;45(1):115–20.PubMedPubMedCentralCrossRef Dvivedi J, Dvivedi S. A clinical and demographic profile of the cleft lip and palate in sub-Himalayan India: a hospital-based study. Indian J Plast Surg. 2012;45(1):115–20.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Klion AD. Eosinophilia: a pragmatic approach to diagnosis and treatment. Hematology. 2015;2015(1):92–7.PubMedCrossRef Klion AD. Eosinophilia: a pragmatic approach to diagnosis and treatment. Hematology. 2015;2015(1):92–7.PubMedCrossRef
17.
Zurück zum Zitat Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27(2):277–301.PubMedPubMedCentral Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27(2):277–301.PubMedPubMedCentral
18.
Zurück zum Zitat Sinico RA, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926–35.PubMedCrossRef Sinico RA, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926–35.PubMedCrossRef
19.
Zurück zum Zitat Sablé-Fourtassou R, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143(9):632–8.PubMedCrossRef Sablé-Fourtassou R, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143(9):632–8.PubMedCrossRef
21.
Zurück zum Zitat Wakasa K, et al. Primary tracheobronchial amyloidosis. A case report and review of reported cases. Acta Pathol Jpn. 1984;34(1):145–52.PubMed Wakasa K, et al. Primary tracheobronchial amyloidosis. A case report and review of reported cases. Acta Pathol Jpn. 1984;34(1):145–52.PubMed
22.
Zurück zum Zitat Gibbaoui H, Abouchacra S, Yaman M. A case of primary diffuse tracheobronchial amyloidosis. Ann Thorac Surg. 2004;77(5):1832–4.PubMedCrossRef Gibbaoui H, Abouchacra S, Yaman M. A case of primary diffuse tracheobronchial amyloidosis. Ann Thorac Surg. 2004;77(5):1832–4.PubMedCrossRef
23.
Zurück zum Zitat Ozer C, et al. Primary diffuse tracheobrochial amyloidosis: case report. Eur J Radiol. 2002;44(1):37–9.PubMedCrossRef Ozer C, et al. Primary diffuse tracheobrochial amyloidosis: case report. Eur J Radiol. 2002;44(1):37–9.PubMedCrossRef
24.
Zurück zum Zitat Li D, et al. Primary tracheobronchial amyloidosis: coronal CT scan may provide clues for early diagnosis. J Postgrad Med. 2013;59(3):223–5.PubMedCrossRef Li D, et al. Primary tracheobronchial amyloidosis: coronal CT scan may provide clues for early diagnosis. J Postgrad Med. 2013;59(3):223–5.PubMedCrossRef
25.
26.
Zurück zum Zitat Lu X, et al. Bronchoscopic diagnosis and treatment of primary tracheobronchial amyloidosis: a retrospective analysis from China. Biomed Res Int. 2017;2017:3425812.PubMedPubMedCentral Lu X, et al. Bronchoscopic diagnosis and treatment of primary tracheobronchial amyloidosis: a retrospective analysis from China. Biomed Res Int. 2017;2017:3425812.PubMedPubMedCentral
27.
Zurück zum Zitat Vassallo R, Harari S, Tazi A. Current understanding and management of pulmonary Langerhans cell histiocytosis. Thorax. 2017;72(10):937–45.PubMedCrossRef Vassallo R, Harari S, Tazi A. Current understanding and management of pulmonary Langerhans cell histiocytosis. Thorax. 2017;72(10):937–45.PubMedCrossRef
28.
Zurück zum Zitat Roden AC, Yi ES. Pulmonary Langerhans cell Histiocytosis: an update from the Pathologists’ perspective. Arch Pathol Lab Med. 2016;140(3):230–40.PubMedCrossRef Roden AC, Yi ES. Pulmonary Langerhans cell Histiocytosis: an update from the Pathologists’ perspective. Arch Pathol Lab Med. 2016;140(3):230–40.PubMedCrossRef
29.
Zurück zum Zitat Dimmler A, et al. Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis. Virchows Arch. 2017;470(4):429–35.PubMedCrossRef Dimmler A, et al. Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis. Virchows Arch. 2017;470(4):429–35.PubMedCrossRef
30.
Zurück zum Zitat Lommatzsch M, et al. Bronchoalveolar lavage for the diagnosis of pulmonary Langerhans cell histiocytosis. Respir Med. 2016;119:168–74.PubMedCrossRef Lommatzsch M, et al. Bronchoalveolar lavage for the diagnosis of pulmonary Langerhans cell histiocytosis. Respir Med. 2016;119:168–74.PubMedCrossRef
31.
Zurück zum Zitat Schilder AM. Wegener’s Granulomatosis vasculitis and granuloma. Autoimmun Rev. 2010;9(7):483–7.PubMedCrossRef Schilder AM. Wegener’s Granulomatosis vasculitis and granuloma. Autoimmun Rev. 2010;9(7):483–7.PubMedCrossRef
32.
Zurück zum Zitat Patten SF, Tomecki KJ. Wegener’s granulomatosis: cutaneous and oral mucosal disease. J Am Acad Dermatol. 1993;28(5 Pt 1):710–8.PubMedCrossRef Patten SF, Tomecki KJ. Wegener’s granulomatosis: cutaneous and oral mucosal disease. J Am Acad Dermatol. 1993;28(5 Pt 1):710–8.PubMedCrossRef
33.
Zurück zum Zitat Provenzale JM, Allen NB. Wegener granulomatosis: CT and MR findings. AJNR Am J Neuroradiol. 1996;17(4):785–92.PubMed Provenzale JM, Allen NB. Wegener granulomatosis: CT and MR findings. AJNR Am J Neuroradiol. 1996;17(4):785–92.PubMed
34.
Zurück zum Zitat Gross WL, Trabandt A, Csernok E. Pathogenesis of Wegener's granulomatosis. Ann Med Interne (Paris). 1998;149(5):280–6. Gross WL, Trabandt A, Csernok E. Pathogenesis of Wegener's granulomatosis. Ann Med Interne (Paris). 1998;149(5):280–6.
35.
Zurück zum Zitat Wu JJ, Schiff KR. Sarcoidosis. Am Fam Physician. 2004;70(2):312–22.PubMed Wu JJ, Schiff KR. Sarcoidosis. Am Fam Physician. 2004;70(2):312–22.PubMed
36.
Zurück zum Zitat Costabel U, Hunninghake GW. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–55. Costabel U, Hunninghake GW. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–55.
37.
Zurück zum Zitat Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and Management of Sarcoidosis. Am Fam Physician. 2016;93(10):840–8.PubMed Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and Management of Sarcoidosis. Am Fam Physician. 2016;93(10):840–8.PubMed
38.
Zurück zum Zitat Callister ME, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 2015;70(Suppl 2):ii1–ii54.PubMedCrossRef Callister ME, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 2015;70(Suppl 2):ii1–ii54.PubMedCrossRef
Metadaten
Titel
Extensive eye-oral-bronchial mucosal nodules with eosinopgillia: a rare case report and literature review
verfasst von
Lujin Wu
Qianru Leng
Yan Wang
Daowen Wang
Danlei Yang
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Pulmonary Medicine / Ausgabe 1/2020
Elektronische ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-020-01340-2

Weitere Artikel der Ausgabe 1/2020

BMC Pulmonary Medicine 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.